Who are ETN+MTX's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Infliximab, methylprednisolone, methotrexate, Etanercept + Methotrexate, Anti TNF + Meth.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/etn-mtx.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

ETN+MTX — Competitive Intelligence Brief

ETN+MTX (ETN+MTX) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: TNF inhibitor + DMARD combination. Area: Immunology.

marketed TNF inhibitor + DMARD combination TNF-α receptor; dihydrofolate reductase Immunology Small molecule Live · refreshed every 30 min

Target snapshot

ETN+MTX (ETN+MTX) — Japan Biological Agent Study Integrated Consortium. ETN+MTX is a combination therapy of etanercept (TNF inhibitor) and methotrexate that suppresses tumor necrosis factor and reduces immune-mediated inflammation.

Comparator set (3 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
ETN+MTX TARGET	ETN+MTX	Japan Biological Agent Study Integrated Consortium	marketed	TNF inhibitor + DMARD combination	TNF-α receptor; dihydrofolate reductase
Infliximab, methylprednisolone, methotrexate	Infliximab, methylprednisolone, methotrexate	Université Catholique de Louvain	marketed	TNF-α inhibitor combination therapy	TNF-α receptor; dihydrofolate reductase; glucocorticoid receptor
Etanercept + Methotrexate	Etanercept + Methotrexate	Wyeth is now a wholly owned subsidiary of Pfizer	marketed	TNF inhibitor + DMARD combination	TNF-alpha receptor (etanercept); dihydrofolate reductase (methotrexate)
Anti TNF + Meth	Anti TNF + Meth	Hamad Medical Corporation	phase 3	TNF inhibitor + DMARD combination	TNF-α receptor / Dihydrofolate reductase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (TNF inhibitor + DMARD combination class)

Hamad Medical Corporation · 1 drug in this class
Japan Biological Agent Study Integrated Consortium · 1 drug in this class
Wyeth is now a wholly owned subsidiary of Pfizer · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). ETN+MTX — Competitive Intelligence Brief. https://druglandscape.com/ci/etn-mtx. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab